-
1 Comment
ProPhase Labs, Inc is currently in a long term downtrend where the price is trading 22.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.0.
ProPhase Labs, Inc's total revenue rose by 64.4% to $5M since the same quarter in the previous year.
Its net income has dropped by 109.4% to $-978K since the same quarter in the previous year.
Finally, its free cash flow fell by 1648.4% to $-8M since the same quarter in the previous year.
Based on the above factors, ProPhase Labs, Inc gets an overall score of 2/5.
| Industry | Drug Manufacturers-Specialty & Generic |
|---|---|
| Sector | Healthcare |
| ISIN | US74345W1080 |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Market Cap | 146M |
|---|---|
| PE Ratio | 8.32 |
| Beta | -0.37 |
| Dividend Yield | 13.% |
| Target Price | 15.5 |
ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PRPH using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
